Journal article

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Abstract:: Background
COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply constraints are considering administering a third dose. We assessed the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44–45 weeks) between the first and second dose, and response to a thir... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Flaxman, A., Marchevsky, N. G., Jenkin, D., Aboagye, J., Aley, P. K., Angus, B., Belij-Rammerstorfer, S., Bibi, S., Bittaye, M., Cappuccini, F., Cicconi, P., Clutterbuck, E. A., Davies, S., Dejnirattisai, W., Dold, C., Ewer, K. J., Folegatti, P. M., Fowler, J., Hill, A. V. S., … Lambe, T. (2021). Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, 398(10304), 981–990.

MLA Style

Flaxman, A., et al. “Reactogenicity and Immunogenicity after a Late Second Dose or a Third Dose of ChAdOx1 NCoV-19 in the UK: a Substudy of Two Randomised Controlled Trials (COV001 and COV002).” Lancet, vol. 398, no. 10304, Elsevier, 2021, pp. 981–90.

Chicago Style

Flaxman, A, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, S Belij-Rammerstorfer, et al. 2021. “Reactogenicity and Immunogenicity after a Late Second Dose or a Third Dose of ChAdOx1 NCoV-19 in the UK: a Substudy of Two Randomised Controlled Trials (COV001 and COV002).” Lancet 398 (10304): 981–90.
Share
Print

Access Document

Files:: Flaxman_et_al_2021_Reactogenicity_and_immunogenicity.pdf

(Preview, Version of record, 3.7MB, Terms of use)

Publisher copy:: 10.1016/S0140-6736(21)01699-8

Authors

+ Flaxman, A More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Marchevsky, NG More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Paediatrics
Role:: Author

+ Jenkin, D More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Aboagye, J More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Aley, PK More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Paediatrics
Role:: Author
ORCID:: 0000-0002-0749-8329

More authors...

Contributors

+ Oxford COVID Vaccine Trial group

Role:: Contributor

Publisher:: Elsevier
Journal:: Lancet More from this journal
Volume:: 398
Issue:: 10304
Pages:: 981-990
Publication date:: 2021-09-01
Acceptance date:: 2021-09-01
DOI:: 10.1016/S0140-6736(21)01699-8
EISSN:: 1474-547X
ISSN:: 0140-6736

Language:: English
Keywords:: FFR
Pubs id:: 1193873
Local pid:: pubs:1193873
Deposit date:: 2021-09-03

Terms of use

Copyright holder:: Flaxman et al.
Copyright date:: 2021
Rights statement:: Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP